Development, open of Then Product Benkowitz, to Financial going I'd Mike the start the beginning And Vice will a to Edgemond over and looking offer Officer providing Chief of continue to Officer, I'm everybody. for they to to on here Peterson. you overview James we like first or morning, can we'll operating President Michael the toward mike past or Operating the back either Good end the are results the to or Dr. President I quarter turn our directed quarter. to Leigh and questions Chief how Dewey. to at you, or call of then be our he Thank company. second up our and the month of the
So that those I sustainable. what's label have I think themes looking the quarter. stronger, as And were I key back summarize on the stable, gone would really past on themes past three three quarter, in that to there and
delve in of So each pandemic. of let stronger mean in a words of me concepts about sustainable and the into what this and of talk -- for stable, middle COVID context Therapeutics in or right concept United the the moment those
essential glad drug we stable, what this really manufacturing, So that share laboratories pandemic. COVID Massachusetts theme, have from offices very been Carolina, am the one notwithstanding distribution, research as our call and facilities. of have to from from all Therapeutics biomedical past Hampshire I remained United Maryland to to open Virginia, reimbursement Every production and during and the North to first New and the quarter, stable California Florida,
staff has these facilities regards. a all Our maintain occupancy distancing reduce in to to on and shift basis continued physical operate to
that I drug on report patients, finished considerable of to has happy pharmacies, they've Indeed, years and United distributors. two all in doctors, I'm than report that relief drug finished maintain our of drug amount result, us and customary even has inventory two enabled As numbers a quarter shipping than production normal to past our still more the while out this to years can reported more knowing inventory. very Therapeutics of
of years the in U.S. here our on at two In precursors the to on years' own Therapeutics. laboratories top finished worth that, chemical three for making we in here also all of drug the site addition our have at hand additional United
our concept U.S.A. start based much And clinical you is trials. to distribution our provides that to core provide of provide the in everybody I relief context get medicines the right for with patients medicines purpose the of five the to for stability So in here all all even core Therapeutics, to we life, and so down to the provide is the in of reason the stable production, are United think told, when patients, I drug purpose its years medicines the to reason review to
that including devices So with delivery the and all part drug that of parcel we've of that. done are
So in stable. is to first of say end of quarter middle pandemic I'm happy that UT the the at the the
Second main about stronger. is to talk like theme I'd
to our pipeline. Here I'm referring
stronger was this trials strong as III very great and because before we was pipeline of Our It before quarter past now. Phase underway. even strong it's had
is that the Ralinepag pandemic One trial even patients. of while going we new trials that and able prostacyclin in not we enroll keep them able trial clinical patients I that I think agonist trial most should been been the trial have we've to and the exciting continue worldwide best-in-class material to is say to this undergoing you know to during provide
exciting. that's So very
to of large able We that not results -- that new Same we're III for the pulmonary a hypertension Phase pulmonary to it also type keep had COPD but also we're our we TYVASO for of going story, have up on open very able trial. very, based COPD underway market trials III patients, enroll hypertension. will of Phase us
back Our Phase hypertension. trial perhaps gene study, of the SAPPHIRE could course that of really the modify III therapy, turn and pulmonary
data out before the that was trial came of context INCREASE strong quarter, absolute of had quarter in out but came pipeline disease. this of interstitial a lung most the we exciting of So that the of this our things TYVASO one super
we TYVASO work and reported, into be variant. our supplemental X Group expansion Now, trial. of of label full specifically our file primary we notwithstanding disease interstitial of pandemic, to the continue hypertension on endpoints And for pulmonary all as for we'd to the NDA as a the COVID INCREASE our lung that schedule speed hit secondary team they
but who for, as in approved X And was the this just before pulmonary mentions to for than some this hypertension X addressing proven new of Group which be INCREASE the types new successful current of Group pulmonary or here, the this drugs to is the and a ventilation which type to story you disease drug that the our to hypertension larger lung possible may of really pulmonary is all are it's disease reason involving mismatch. disease interstitial the bad very for so vasculature, not the specifically treat drugs that systemic and without giving that And successfully effect obstruction rise pulmonary called restriction -- this airways hypertension, of the the a perfusion with variant. is consequence trial side
There's is TYVASO, practical just possibilities very to day a inhalation. a minutes minutes inhale times treating for only are practical drug iloprost a be without V/Q two of the there times which two triggering is nine drug, day, mismatch. not So XX four needing very for upwards really inhaled which a shot or this
patients disease Well, to way, they approval in had capacity fibrosis. type and better spectacular the reported, we type were vital product years, the of we And able had do launch summer this the was with slow these really that reversing who has drugs. early did from not the of we drugs, that But pulmonary on called the interstitial expect disease by the placebo. potent one a patients IPF. forced approved two that a INCREASE than And were What stellar quarter XXXX. results lung of degradation FDA was in two in what trial that was made most to the the of already, trial. about over and are and filing And our results really stronger and as patients pipelines we're of
at So the didn't they patients rate they condition, slowed just were improve patient's the which degrading. the
are just by who of of in improve INCREASE top vital the treating capacity but the the trial. background already patients Prescient And our the two greater than drugs be was capacity for in fibrosis. the have pirfenidone drug fibrosis. because in is forced patients' nintedanib on forced of other done fibrosis secondary endpoint it the hypertension a the a of say team fibrosis because was by their have pulmonary and care the in registration approved for patients the or for is improvement amount were pulmonary FVC vital Now, able a trials. approval to with FVC that as had of prescient top pulmonary We standard that's for those of that this approved endpoint drugs I on would necessary pulmonary fact the think endpoint I looked pulmonary at FDA to drug not treating
for like registration trial modifying a a developer, sizing this was you've all of in of we by tested So icing these a slowed patient's where in you on actually on background top pulmonary already approved effect clinical were fibrosis even this degradation. of a drug FVC, approved the like already is therapies is this not eight disease hypothesis to just their up those background had accomplish therapies. for situation rate And that a the on the approved And weeks. then only patients registration the able see -- And improved it case the to TYVASO already had confirm improving best here they cake, with trial. want you FVC an
So and is is end demonstrated an FVC show eight the of mentioned, the than nintedanib in improvement all. and didn't until that pirfenidone already improved this maintained fact improvement much at weeks which patients of improvement the onset This in randomized, faster after marked trial. of was we in saw studies, were the was actually a clinical much
short will and disease. id specify up process now Phase a to of type the CFILD this, interstitial on trial known a fibrosis design that chronic fibrosis. specific that have new opening call be it'll for be as mouthful. I in just And pulmonary in based So III we been that's able and of begin a CFILD, lung
is INCREASE Phase by also IND with the work will in for quarter III year this trial. new together TRITON right this enrolling the are of in IND first together the putting the name the of that plan and the summer and and approvals registration III And putting during half INCREASE begin get of third this in trial fourth -- CFILD. get the the patients parallel we the that the Phase our IRB on And XXXX. for for call we the achieve trial quarter really TRITON trial close So the of tails we sNDA for our latter IFD sNDA that and in our then CFILD to we in that
the I'm cancer, has time mention United why this. thing excited is pulmonary other hypertension. first undertaken franchise its one activities that the our Therapeutics -- than of in an this is so me about really beyond other Let expansion This
don't confuse this be this indication, Just who CFILD in patients will fibrosis so I indication didn't like here, have pulmonary hypertension. somebody
the about about quarter number times But the I with larger, Now INCREASE had the four a pulmonary pulmonary fibrosis hypertension fibrosis. pulmonary well pulmonary in patients patients over mentioned in who is XXX,XXX without have the fact, of of the the hypertension patients.
first a be larger Therapeutics several study the So to this will of hypertension non-cancer in appears that the action those than the to FVC the based that improvement modifying is upon times Phase and of embark disease on finally pulmonary patient quarter United III of study the mechanism hypertension in field that XXXX pulmonary patients. in in and with be on positive first a showing TRITON population us of will actually population, outside
expanding a larger several first times with hypothesis before. from all a addressing had that pulmonary doing data-backed XXXX hypertension the hypertension, with the pulmonary by and So emerged told, doubt beyond think of have pipeline population we really is in solidly quarter than even that then there than no we're and I stronger so we patient
fortunate Michael various been want hypertension There is COVID disproportionally impacted talk turning The our to blessed I hypothesis over not that would this that why is. hypertension and theme very say community pulmonary population. are I third very has about to sustainable. that has of pulmonary It's before entire the things
the population not are have condition than this much lung maintaining The know extraordinary Razor impacted is there that other some other PH careful to already distancing of event COVID that people think in and more the they caution the populations. compared the statistically realize probably adversely Occam's population they for it's with to published has to and patients are necessary. physical so any any you on I But in of due respect kind the cancer care distancing. heart articles
COVID that be sustainably do the will believe of we to pulmonary go pandemic. I what hypertension population to as So continue help able we our through remains
as aspect margins and past, that see for of and our we is been sustainable. revenues can all are the quarterly they've that sustainability they are as released see, our we in you'll Another profit in today, good financials quite
in about all XX% pumps able in talked we Transformative have our safe maintain has know on I invest this are to Officer everybody profitability ensure coming Financial schedule the Chief for that launch our and continued the Pump setting proper July. right budget manufacturing we As mark a of to technologies to out, continue year times, of in maximum our remains the previous spacing during doing revenues. technologies by our budget which many the the within manufacturing to And pipeline. algorithm at those shifts, the such as The Remodulin, themselves Again, thing. folks Remunity pandemic. and all transformative is
system implantable site completely ISR the rid Remodulin, of pain. of painless get The for treprostinil issue RemoPro, the to system, analogues of
were of the do this profit of the of because All we able constant to level against sustainably the revenues. margin of maintenance
like market We the continue Ralinepag the expanding hypertension, also as I at to beginning. for mentioned fund products pulmonary
work, The We III pulmonary have related Phase perfect gene mentioned hypertension. therapy study this COPD of I previously.
R&D take which using med to an manufacturing of of we're against And efforts growth quarter. that outcome have that then, enable case sustainable to that Orenitram several seen us the situations. region have new to we're once fortunate product challenges our cash on such the revenue COVID margins Exosome the now worst art that flow as build these in continue on to sequelae form We past directing excellent that you've research enable to also daily will treat us is a COVID of run
As kidneys, of paradigm slide of manufacturing organ unlimited transplantation. produce new transplantable organ well to literally example, create an would that as supply a for
full sustainable. once in all So and has am I change a of absolutely that United in lifetime adaptiveness to in how stronger, environment well demonstrated stable, nimbleness experiencing. its we're pride Therapeutics a
President to and Officer. Operating to Benkowitz, like I'd Michael? Chief over overview, Mike turn that our mike the With now
